Advanced search
1 file | 339.42 KB Add to list

Medical treatment in coronary patients : is there still a gender gap? Results from European Society of Cardiology EUROASPIRE V Registry

Author
Organization
Abstract
Purpose This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). Methods Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (>= 6 months to < 2 years after hospitalization) was collected. Results Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%;P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%;P < 0.001) and calcium channel blockers (21.2% vs. 28.8%;P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%;P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%;P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. Conclusion The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.
Keywords
Pharmacology (medical), Pharmacology, Cardiology and Cardiovascular Medicine, General Medicine, EUROASPIRE, Medical treatment, Cardiovascular diseases, Gender, CARDIOVASCULAR RISK-FACTORS, HEART-DISEASE, MYOCARDIAL-INFARCTION, SEX-DIFFERENCES, PREVENTION, MANAGEMENT, SYMPTOMS, OUTCOMES, WOMEN, AGE

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 339.42 KB

Citation

Please use this url to cite or link to this publication:

MLA
Vynckier, Pieter, et al. “Medical Treatment in Coronary Patients : Is There Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry.” CARDIOVASCULAR DRUGS AND THERAPY, vol. 35, no. 4, 2021, pp. 801–08, doi:10.1007/s10557-020-07095-6.
APA
Vynckier, P., Ferrannini, G., Rydén, L., Tokgözoğlu, L., Bruthans, J., Kotseva, K., … On behalf of the EUROASPIRE V Investigators group, [missing]. (2021). Medical treatment in coronary patients : is there still a gender gap? Results from European Society of Cardiology EUROASPIRE V Registry. CARDIOVASCULAR DRUGS AND THERAPY, 35(4), 801–808. https://doi.org/10.1007/s10557-020-07095-6
Chicago author-date
Vynckier, Pieter, Giulia Ferrannini, Lars Rydén, Lale Tokgözoğlu, Jan Bruthans, Kornelia Kotseva, David Wood, et al. 2021. “Medical Treatment in Coronary Patients : Is There Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry.” CARDIOVASCULAR DRUGS AND THERAPY 35 (4): 801–8. https://doi.org/10.1007/s10557-020-07095-6.
Chicago author-date (all authors)
Vynckier, Pieter, Giulia Ferrannini, Lars Rydén, Lale Tokgözoğlu, Jan Bruthans, Kornelia Kotseva, David Wood, Tine De Backer, Sofie Gevaert, Dirk De Bacquer, Delphine De Smedt, and [missing] On behalf of the EUROASPIRE V Investigators group. 2021. “Medical Treatment in Coronary Patients : Is There Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry.” CARDIOVASCULAR DRUGS AND THERAPY 35 (4): 801–808. doi:10.1007/s10557-020-07095-6.
Vancouver
1.
Vynckier P, Ferrannini G, Rydén L, Tokgözoğlu L, Bruthans J, Kotseva K, et al. Medical treatment in coronary patients : is there still a gender gap? Results from European Society of Cardiology EUROASPIRE V Registry. CARDIOVASCULAR DRUGS AND THERAPY. 2021;35(4):801–8.
IEEE
[1]
P. Vynckier et al., “Medical treatment in coronary patients : is there still a gender gap? Results from European Society of Cardiology EUROASPIRE V Registry,” CARDIOVASCULAR DRUGS AND THERAPY, vol. 35, no. 4, pp. 801–808, 2021.
@article{8687396,
  abstract     = {{Purpose This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). Methods Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (>= 6 months to < 2 years after hospitalization) was collected. Results Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%;P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%;P < 0.001) and calcium channel blockers (21.2% vs. 28.8%;P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%;P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%;P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. Conclusion The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.}},
  author       = {{Vynckier, Pieter and Ferrannini, Giulia and Rydén, Lars and Tokgözoğlu, Lale and Bruthans, Jan and Kotseva, Kornelia and Wood, David and De Backer, Tine and Gevaert, Sofie and De Bacquer, Dirk and De Smedt, Delphine and On behalf of the EUROASPIRE V Investigators group, [missing]}},
  issn         = {{0920-3206}},
  journal      = {{CARDIOVASCULAR DRUGS AND THERAPY}},
  keywords     = {{Pharmacology (medical),Pharmacology,Cardiology and Cardiovascular Medicine,General Medicine,EUROASPIRE,Medical treatment,Cardiovascular diseases,Gender,CARDIOVASCULAR RISK-FACTORS,HEART-DISEASE,MYOCARDIAL-INFARCTION,SEX-DIFFERENCES,PREVENTION,MANAGEMENT,SYMPTOMS,OUTCOMES,WOMEN,AGE}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{801--808}},
  title        = {{Medical treatment in coronary patients : is there still a gender gap? Results from European Society of Cardiology EUROASPIRE V Registry}},
  url          = {{http://dx.doi.org/10.1007/s10557-020-07095-6}},
  volume       = {{35}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: